Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC — Stella

Home/Squamous Cell Carcinoma of Head and Neck/5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

View on ClinicalTrials.gov

Recruiting

Back to Squamous Cell Carcinoma of Head and Neck trials

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Yale University, New Haven, Connecticut

Key details

Phase

Safety & dosing

Sponsor

Barbara Burtness

Collaborators

National Institute of Dental and Craniofacial Research (NIDCR)

Enrollment target

~50 participants

Started

March 2023

Primary completion

June 2028

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.